Verisante Technology, Inc. Announces Submission to the FDA for Aura(TM), a Skin Cancer Detection Device

October 1, 2014 12:02 PM

13 0

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 10/01/14 -- Verisante Technology, Inc. (TSX VENTURE: VRS)(OTCQX: VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today it has initiated communications with the Food and Drug Administration ("FDA") in the United States for the approval of Aura™, a device for the detection of skin cancer.

"Verisante has now submitted documents to the FDA as we begin the formal application process for approval to market and sell Aura™ in the United States," said Thomas Braun. "We look forward to working closely with the FDA to receive further guidance and feedback on our regulatory pathway."

Read more

To category page